We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


29 July 2016 By Una Galani

The Chinese conglomerate’s drug unit is buying India’s Gland Pharma for up to $1.3 bln. Shortages should boost prices of injectable drugs in the U.S., a key market for the KKR-backed group. Either way, Fosun’s latest deal binge jars with its promise to cut debt.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)